| Code | CSB-RA013510MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to CM-338, developed for research targeting Mannan-binding lectin serine protease 2 (MASP2). MASP2 is a critical effector enzyme of the lectin pathway of complement activation, one of three major routes by which the complement system recognizes pathogens and altered self-cells. Upon binding of pattern recognition molecules to target surfaces, MASP2 undergoes autoactivation and cleaves complement components C4 and C2, initiating the complement cascade. Dysregulated MASP2 activity has been implicated in various pathological conditions including ischemia-reperfusion injury, thrombotic microangiopathies, age-related macular degeneration, and antibody-mediated transplant rejection.
CM-338 (narsoplimab) is a fully humanized IgG4 monoclonal antibody that specifically inhibits MASP2 enzymatic activity, thereby blocking lectin pathway-mediated complement activation while preserving the classical and alternative pathways. This biosimilar provides researchers with a valuable tool for investigating lectin pathway mechanisms, studying complement-mediated diseases, and exploring therapeutic strategies targeting MASP2 in preclinical models.
There are currently no reviews for this product.